Androgens improve cavernous vasodilation and response to @entity7855 in @entity1 with XXXX .

@entity1 @entity323 @entity251 @entity72459 @entity1674 @entity53 @entity7855 @entity165 @entity342 @entity1486 @entity443
OBJECTIVES: We have recently shown that, in @entity1 with @entity323 ( @entity323 ), free @entity251 (FT) directly correlates with penile arterial inflow. This led us to further investigate the effect(s) of @entity342 administration on cavernous arteries in @entity1 failing @entity7855 treatment. DESIGN: Prospective randomized placebo-controlled pilot study. @entity1 : Twenty @entity1 with arteriogenic @entity323 as evaluated by dynamic colour duplex ultrasound ( @entity72459 ) studies, normal sexual desire but @entity251 (T) and FT in the lower quartile of normal range (low-normal), not responding to @entity7855 treatment (100 mg) on six consecutive attempts. MEASUREMENTS: All @entity1 had @entity72459 , hormonal [LH, @entity1486 (PSA), total and free @entity251 , @entity443 ( @entity443 ), @entity53 ], biochemical [haematocrit, low-density lipoprotein (LDL) and HDL @entity165 , @entity1674 ], and sexual evaluations [International Index of Erectile Function (IIEF)] before and after 1 month of therapy with transdermal @entity251 (5 mg/day, n = 10) or placebo along with @entity7855 treatment on demand. Measurement of flow parameters by @entity72459 on cavernous arteries was the primary endpoint of the study. Improvement of erectile function was assessed using the IIEF questionnaire and the Global Assessment Question (GAQ). RESULTS: One month treatment with transdermal @entity251 led to a significant increase in T and FT levels (23.7 +/- 3.3 SD vs. 12.8 +/- 2.1 nmol/l and 473 +/- 40.2 vs. 260 +/- 18.1 pmol/l, P < 0.01, respectively). In addition @entity251 administration induced a significant increase in arterial inflow to cavernous arteries measured by @entity72459 (32 +/- 3.6 vs. 25.2 +/- 4 cm/s, P < 0.05), with no adverse effects. Also, a significant improvement in erectile function domain score at IIEF was found in the @entity342 but not in the placebo-treated @entity1 (21.8 +/- 2.1 vs. 14.4 +/- 1.4, P < 0.05) which was associated with significant changes in the GAQ score (80%vs. 10%, P < 0.01). CONCLUSIONS: In @entity1 with arteriogenic @entity323 and low-normal @entity342 levels, short-term @entity251 administration increases T and FT levels and improves the erectile response to @entity7855 likely by increasing arterial inflow to the penis during sexual stimulation.
